SCLEROSING PERITONITIS, AN UNUSUAL REACTION TO a Β-Adrenergic-Blocking DRUG (PRACTOLOL)

Brown, Peter; Read, A. E.; Baddeley, H.; Davies, J.; McGarry, John J.

doi:10.1016/s0140-6736(74)90218-9

Cited by 242 publications

(95 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So his use of betablockers seems to be a possible cause of the SEP, which is consistent with the literature [3]. The classic beta blocker that was associated with SEP is practolol in 1974 [13], being withdrawn from the market in 1975. Since then many case reported with other beta blockers like atenolol propranolol, timolol, metoprolol and sotalol [3,21].…”

Section: Daily Infusion Compounded In Multilayer Bagsupporting

confidence: 83%

“…The most common identified cause of this rare condition is continuous ambulatory peritoneal dialysis but other causes like beta blockers could be a cause as well (Table 1) [7][8]. Other associations reported in the literature include ovarian thecomas, tuberculous pelvic inflammatory disease, ventriculoperitonealshunts, systemic lupus erythematosus, orthotopic liver transplantation, protein S deficiency, ovarian cysts, keratoconjunctivitis sicca syndrome and various beta adrenergic blocking agents [3,5,[9][10][11][12][13].…”

Section: Daily Infusion Compounded In Multilayer Bagmentioning

confidence: 99%

See 1 more Smart Citation

Review of the Literature and Description of a Case of Sclerosing Encapsulating Peritonitis Requiring Home Parenteral Nutrition

et al. 2011

View full text Add to dashboard Cite

We present a case of a 48 year old HIV patient, who had recurrent episodes of ascites since 2007. His history includes ischaemic heart disease, for which he was treated with atenolol from 2005 to 2007, and Type 2 diabetes; he was later started on propranolol 40mg twice a day from 2007 for Didanosine-induced portal hypertension. Because of negative cultures and neutrophil count < 250 cells/μL, spontaneous bacterial peritonitis was excluded. However, some low grade-peritoneal irritation cannot be ruled out because his CRP varied from 24 to 258, during 2007-2009, without any other obvious inflammatory cause. He was finally diagnosed in July 2009 with sclerosing encapsulating peritonitis (SEP) based on clinical features of intestinal obstruction, histology and imaging, including computed tomography and magnetic resonance imaging. Propranolol was stopped in November 2009. Because of the patient's severe intestinal obstruction, he was started on parenteral nutrition 2L/day. Since then, his CRP has returned to normal levels and there is a great improvement of his clinical features. This case demonstrates beta-blockers as a potential cause of SEP, while the presence of some low-grade peritoneal inflammation leading to SEP is also very likely.

show abstract

Section: Daily Infusion Compounded In Multilayer Bagsupporting

confidence: 83%

Section: Daily Infusion Compounded In Multilayer Bagmentioning

confidence: 99%

Review of the Literature and Description of a Case of Sclerosing Encapsulating Peritonitis Requiring Home Parenteral Nutrition

et al. 2011

View full text Add to dashboard Cite

show abstract

“…8 Beta blockers have been remotely reported as a rare culprit for SEP in single-case reports. [13][14][15] The presenting symptoms and signs of SEP such as nausea, vomiting, fullness, absent bowel sounds, abdominal pain, abdominal or pelvic mass and other clinical aspects are often nonspecific that may be seen in a variety of conditions. 1 SEP is therefore often diagnosed at laparotomy or autopsy.…”

Section: Discussionmentioning

confidence: 99%

Sclerosing encapsulating peritonitis

Pan

Thosani

Fallon

2012

Gastroenterol Insights

View full text Add to dashboard Cite

Sclerosing encapsulating peritonitis (SEP) is a rare cause of intestinal obstruction. This entity has been reported as either primary idiopathic or secondary to other diseases. We report SEP in 2 cirrhotic patients and review the literature. Both patients had decompensated cirrhosis and episodes of spontaneous bacterial peritonitis. One patient underwent a Denver shunt placement before developing SEP. This patient remains alive and is managed conservatively. The other patient deceased from multi-organ failure after the resection of gangrened small bowel. The manifestations of SEP are often nonspecific that leads to misdiagnosis and/or delayed diagnosis. Early diagnosis of SEP is difficult but not impossible. Surgical treatment is often required when intestinal obstruction is present. Nevertheless, patients with this problem can be treated conservatively with immunosuppressive therapy with or without total parenteral nutrition (TPN) before going for surgery.

show abstract

“…[18] Proposed mechanisms involve decline of residual renal function, development of sclerosing encapsulated peritonitis, [19][20][21][22] increased glucose absorption due to increase in number and function of glucose transporters in peritoneum membrane, [23] decreased portal venous pressure, [24][25][26] increased lymphatic absorption, and increased capillary density. [27,28] In Stegmayr's study, [18] ultrafiltration failure was detected in 12 patients who used b blocker (mean time of atenolol, pindolol, and metoprolol therapy = 7 months) for hypertension and atrial fibrillation.…”

Section: Discussionmentioning

confidence: 99%

Comparative Effects of Carvedilol and Lercanidipine on Ultrafiltration and Solute Transport in CAPD Patients

Topal¹,

Erkoç

Sayarlıoğlu

et al. 2009

Renal Failure

View full text Add to dashboard Cite

Background. Peritonitis, the type of buffer used in the dialysate, continue ambulatory peritoneal dialysis (CAPD) of greater than two years duration, increased exposure to dialysate glucose, diabetes mellitus, and the use of beta blockers may contribute to impaired ultrafiltration. Objectives. The aim of the present study is to compare the effects of a calcium-channel blocker and a b-blocker on the peritoneal transport and clearance. Methods. We studied 48 patients with ESRD on chronic peritoneal dialysis, included 27 females and 19 males with mean age 42.6 ± 16.4 years. Two patients were excluded from the study due to peritonitis. Patients were treated either with carvedilol or lercanidipine. In all patients; peritoneal equilibration test (PET), ultrafiltration (UF), Kt/V ratio, creatinine clearance (CrCl), systolic blood pressure, diastolic blood pressure, serum BUN, creatinine, glucose, sodium, potassium, albumin, cholesterol, and triglyceride values were obtained before and after 8 weeks from the start of the drug treatment. Results. Lercanidipine and carvedilol showed a good antihypertensive effect in CAPD patients. Both drugs had a good tolerability profile and showed no effect on plasma lipids. There were no differences in terms of PET, ultrafiltration, Kt/V ratio, CrCl, systolic blood pressure, diastolic blood pressure, serum BUN, creatinine, glucose, sodium, and potassium values between both patient groups. After antihypertensive treatment, neither group showed a difference in the above-mentioned parameters (p > 0.05) except potassium, which was significantly higher in the carvedilol group (p < 0.05). Conclusions. In CAPD patients. short-term usage of carvedilol has no effect on ultrafiltration and solute transport like lercanidipine. Both drugs showed a good antihypertensive effect.

show abstract

SCLEROSING PERITONITIS, AN UNUSUAL REACTION TO a Β-Adrenergic-Blocking DRUG (PRACTOLOL)

Cited by 242 publications

References 19 publications

Review of the Literature and Description of a Case of Sclerosing Encapsulating Peritonitis Requiring Home Parenteral Nutrition

Review of the Literature and Description of a Case of Sclerosing Encapsulating Peritonitis Requiring Home Parenteral Nutrition

Sclerosing encapsulating peritonitis

Comparative Effects of Carvedilol and Lercanidipine on Ultrafiltration and Solute Transport in CAPD Patients

Contact Info

Product

Resources

About